#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	18022	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2501	869.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1752	1752	C	1126	C,T	1123,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29978	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4002	933.2	0	.	n	.	0	T695C	SNP	695	695	T	1278	1278	C	1082	C,T,A,G	1076,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29978	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4002	933.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1920	1920	A	1222	A,G,C	1218,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29978	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4002	933.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2554	2554	C	1070	C,A,T	1068,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29978	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4002	933.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2628	2628	A	976	A,G	975,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29978	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4002	933.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3180	3180	C	1069	C,T	1067,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2642	folP	855	855	99.88	folP.l15.c30.ctg.1	2151	153.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1341	1343	AGC	247;247;246	A;G;C	247;247;246	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6002	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3913	191.0	1	SNP	p	S91F	1	.	.	271	273	TTC	905	907	TTC	238;238;237	T,G;T;C	237,1;238;237	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6002	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3913	191.0	1	SNP	p	D95G	1	.	.	283	285	GGC	917	919	GGC	235;236;234	G;G;C,T	235;236;233,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6002	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3913	191.0	1	SNP	p	G95N	0	.	.	283	285	GGC	917	919	GGC	235;236;234	G;G;C,T	235;236;233,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	2394	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	2008	148.7	1	SNP	p	G45D	0	.	.	133	135	GGC	796	798	GGC	255;255;256	G;G,A;C,T	255;254,1;254,2	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1282	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1516	105.4	0	.	n	.	0	A197.	DEL	197	197	A	842	842	A	251	A	251	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3440	210.6	1	SNP	p	D86N	0	.	.	256	258	GAC	811	813	GAC	239;238;238	G;A,C;C	239;237,1;238	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3440	210.6	1	SNP	p	R87W	0	.	.	259	261	CGT	814	816	CGT	238;239;235	C,T;G;T,C,G	237,1;239;233,1,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3440	210.6	1	SNP	p	S87R	1	.	.	259	261	CGT	814	816	CGT	238;239;235	C,T;G;T,C,G	237,1;239;233,1,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3440	210.6	1	SNP	p	R87I	0	.	.	259	261	CGT	814	816	CGT	238;239;235	C,T;G;T,C,G	237,1;239;233,1,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3440	210.6	1	SNP	p	S88P	0	.	.	262	264	TCC	817	819	TCC	239;242;244	T,G;C;C,A,T	238,1;242;242,1,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5136	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3146	203.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1739	1741	GGC	281;277;279	G;G;C,T	281;277;278,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1505	1507	GCA	296;297;296	G;C;A,G	296;297;295,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1508	1510	ATC	295;294;295	A;T;C	295;294;295	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1520	1522	GTG	296;296;295	G,A;T;G	295,1;296;295	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1520	1522	GTG	296;296;295	G,A;T;G	295,1;296;295	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2024	2026	ACC	276;276;275	A;C;C	276;276;275	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2078	2080	GCG	250;249;248	G,A;C;G	249,1;249;248	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2078	2080	GCG	250;249;248	G,A;C;G	249,1;249;248	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2201	2203	AGC	259;259;259	A,G;G;C	257,1;258;258	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2210	2212	GGC	260;261;262	G,C;G,T;C,A	259,1;260,1;261,1	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4848	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2930	206.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2228	2230	CCG	257;259;258	C;C;G	256;259;258	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6690	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3696	225.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1961	1963	CCG	267;265;265	C,G;C;G	266,1;265;265	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2820	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2318	151.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	796	796	C	205	C	205	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	31;32;36	T;T;A	31;32;36	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	69;69;69	C;A;T	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	69;69;69	A;G;T	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	69;69;69	T;A;C	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	6;7;7	G;A;A	6;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	7;7;7	G;C;A	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	7;7;7	A;T;C	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	7;7;7	T;C;G	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	8;10;10	G;C;C	8;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	10;10;9	A;G;C	10;10;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	9;9;9	G;C;C	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	336	porB1a	984	226	90.71	porB1a.l15.c17.ctg.3	319	35.8	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	9;9;9	G;T;T,C	9;9;8,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3560	porB1b	1035	1035	98.76	porB1b.l15.c17.ctg.1	1821	242.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1075	1075	T	281	T,G	279,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3560	porB1b	1035	1035	98.76	porB1b.l15.c17.ctg.1	1821	242.0	1	SNP	p	G120K	0	.	.	358	360	GGT	802	804	GGT	301;302;303	G;G,C;T,C	300;300,1;301,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3560	porB1b	1035	1035	98.76	porB1b.l15.c17.ctg.1	1821	242.0	1	SNP	p	A121D	0	.	.	361	363	GCC	805	807	GCC	301;301;303	G,C;C;C	299,1;300;302	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3560	porB1b	1035	1035	98.76	porB1b.l15.c17.ctg.1	1821	242.0	1	SNP	p	A121N	0	.	.	361	363	GCC	805	807	GCC	301;301;303	G,C;C;C	299,1;300;302	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11890	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5303	279.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1740	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1496	145.0	1	SNP	p	V57M	1	.	.	169	171	ATG	762	764	ATG	275;277;277	A;T,A;G	275;276,1;277	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
